Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095383 | 0.93 | HPGD (0.54) | HPGDTSHRKDM4EMLLT1HSD17B10 | |
| SCHEMBL6880280 | 0.75 | HPGD (0.67) | HPGDKDM4EHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL17957511 | 0.74 | HPGD (0.49) | HPGDLMNATSHRKDM4EMLLT1 | |
| SCHEMBL2026474 | 0.73 | HPGD (1.00) | HPGDKDM4EHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL7704542 | 0.73 | HPGD (0.64) | HPGDTSHRKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10957904 | 0.73 | HSD17B10 (0.54) | HPGDLMNATSHRKDM4EHSD17B10 | |
| SCHEMBL13833222 | 0.72 | HPGD (0.97) | HPGDKDM4EHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL6095609 | 0.72 | HTT (0.49) | HPGDKDM4EALDH1A1DRD4 | |
| SCHEMBL6094239 | 0.71 | MAPT (0.44) | HPGDTSHRKDM4EMLLT1HSD17B10 | |
| SCHEMBL13187311 | 0.70 | DRD2 (0.69) | LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | claimed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | claimed |
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2002092575-A1 | BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | HPGD 4400/4885LMNA 2346/4885TSHR 4745/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | HPGD 4400/4885LMNA 2346/4885TSHR 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.